Filtered By:
Condition: Stroke
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 3663 results found since Jan 2013.

Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke
We report a patient with an active SLE flare who presented with a recurrent ischemic stroke and was found to have numerous unruptured fusiform and saccular aneurysms in multiple vascular territories. He was treated with high-dose steroid and rituximab along with aspirin and blood pressure control for stroke prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2017 Category: Neurology Authors: Shahram Majidi, Christopher R. Leon Guerrero, Shreya Gandhy, Kathleen M. Burger, Dimitri Sigounas Tags: Case Studies Source Type: research

Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke
Background: To explore the association of platelet activation markers, vitamin D, and antiplatelet drugs resistance in ischemic stroke patients. Methods: A total of 230 patients with ischemic stroke were enrolled in this study. Platelet aggregation, platelet activation marker (CD62p), and vitamin D were measured after 7-14 days of dual antiplatelet treatment (aspirin  + clopidogrel). All individuals were divided into a drug resistance group and a drug sensitive group according to the platelet maximum aggregation rate induced by antagonist adenosine diphosphate or arachidonic acid.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2019 Category: Neurology Authors: Bi-Chao Lu, Xiao-Jie Shi, Lin Liang, Na Dong, Zhi-Zhong Liu Source Type: research

Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke
The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial.
Source: Journal of Stroke and Cerebrovascular Diseases - February 6, 2020 Category: Neurology Authors: Scott E. Kasner, Bryan Randall, Grethe Andersen, Helle K. Iversen, Risto Roine, Christina Sjostrand, John F. Rhodes, Lars S øndergaard, The Gore REDUCE Study Investigators Source Type: research

Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial
The effect of interventions on functional impairment is an important outcome in stroke prevention trials and should be considered as an adjunct to counting discrete events. In the NAVIGATE-ESUS trial, 7213 patients with recent embolic strokes of undetermined source were randomized to rivaroxaban (15 mg once daily) or aspirin (100 mg daily). After 11 months there was no effect on the prevention of recurrent stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 12, 2022 Category: Neurology Authors: Jackie Bosch, Lesly A. Pearce, Mukul Sharma, Michelle Canavan, William N. Whiteley, Robert Mikul ík, Hardi Mundl, Salim Yusuf, Robert G. Hart, Martin J. O'Donnell Source Type: research

Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques Major Clinical Trial
Conclusions— Because of lack of power, this trial was inconclusive and results should be taken as hypothesis generating. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00235248.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Amarenco, P., Davis, S., Jones, E. F., Cohen, A. A., Heiss, W.-D., Kaste, M., Laouenan, C., Young, D., Macleod, M., Donnan, G. A., The Aortic Arch Related Cerebral Hazard Trial Investigators, Bladin, Chambers, Frayne, Hankey, Levi, Read, Ravaud, Tatlisuma Tags: Anticoagulants, Antiplatelets Major Clinical Trial Source Type: research

Aspirin Should Be Discontinued After Lobar Intracerebral Hemorrhage Controversies in Stroke
Source: Stroke - September 22, 2014 Category: Neurology Authors: Falcone, G. J., Rosand, J. Tags: Acute Cerebral Hemorrhage, Antiplatelets Controversies in Stroke Source Type: research

Elderly and Forgetful: Is Aspirin Safe for You? Controversies in Stroke
Source: Stroke - September 22, 2014 Category: Neurology Authors: Selim, M. H., Molina, C. A. Tags: Acute Cerebral Hemorrhage, Antiplatelets Controversies in Stroke Source Type: research

Assessment of Platelet Function in Acute Ischemic Stroke Patients Previously Treated with Aspirin
Platelet inhibition measured by platelet function tests could be critical to understand the reasons for early recurrence and to guide therapeutic recommendations. We assess the platelet function during the acute phase of ischemic stroke in patients pretreated with aspirin who continue their treatment with aspirin only, are started on clopidogrel only, or add clopidogrel to aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - October 16, 2014 Category: Neurology Authors: Aida Lago, Vera Parkhutik, Jose Ignacio Tembl, Juana Vallés, Maria Teresa Santos, Antonio Moscardó Source Type: research

The disappearing thrombus: An uncommon cause of ischemic stroke
A 46-year-old woman presented with 2 episodes of transient left-sided paresis and hypoesthesia lasting 30 minutes. The emergency department initiated a stroke code due to reoccurrence of symptoms. Workup revealed a platelet count of 1,141,000, and CT angiography showed a large pedunculated thrombus within the right internal carotid artery (figure 1). She underwent emergent plateletpheresis without an anticoagulant (unfractionated heparin, low molecular weight heparin). This was not started at the time of initial presentation because of increased bleeding risk in patients with either reactive or essential thrombocythemia.1 ...
Source: Nature Clinical Practice - December 8, 2014 Category: Neurology Authors: Lerner, D. P., Graffagnino, C. Tags: Stroke in young adults, All Imaging, Embolism, Infarction Cases Source Type: research

Pathophysiologic, Rather than Laboratory-defined Resistance Drives Aspirin Failure in Ischemic Stroke
A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance. Apart from this clinical description, aspirin resistance can be defined by laboratory tests of in vitro platelet reactivity. The correlation between clinical and laboratory-defined resistance, however, is far from perfect, and the heterogenous nature of stroke pathophysiology might play a role in this discrepancy.
Source: Journal of Stroke and Cerebrovascular Diseases - February 10, 2015 Category: Neurology Authors: Nergiz Agayeva, Levent Gungor, Mehmet Akif Topcuoglu, Ethem Murat Arsava Source Type: research

Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke
We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 “point of care” platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP).
Source: Journal of Stroke and Cerebrovascular Diseases - November 12, 2015 Category: Neurology Authors: Zohara Sternberg, Trevor Chichelli, Daniel Sternberg, Robert Sawyer, Marilou Ching, David Janicke, Julian L. Ambrus, Jinhee Yu, Frederick Munschauer Source Type: research

Cerebral Microbleeds Meta-analyses of Prospective Studies: The Need to Consider Both Ischemic and Hemorrhagic Stroke Outcomes
I read with interest the recent meta-analysis by Wang et al,1 reporting a high risk of intracerebral hemorrhage (ICH) in ischemic stroke/transient ischemic attack patients with cerebral microbleeds—especially those with multiple lesions or taking aspirin. The paper largely corroborates findings of a previous meta-analysis on the topic,2 but also presents some clinically relevant new observations. A key new result is that the presence of a single microbleed (compared to no microbleeds) does not seem to significantly increase the risk of future ICH in this patient population (relative risk: 2.33, 95% confidence interval: ...
Source: Journal of Stroke and Cerebrovascular Diseases - January 13, 2016 Category: Neurology Authors: Andreas Charidimou Tags: Letter to the Editor Source Type: research

Aspirin resistance signals increased stroke severity
Stroke severity and infarct volume are significantly increased among patients who become resistant to aspirin, show study findings published in Neurology.
Source: MedWire News - April 13, 2016 Category: Consumer Health News Tags: Stroke Source Type: news

Ticagrelor no better than aspirin for stroke patients
The direct platelet inhibitor ticagrelor has proved no more effective than aspirin for preventing recurrent events in patients who start treatment within 24 hours of noncardioembolic, nonsevere stroke or high-risk transient ischaemic attack.
Source: MedWire News - May 10, 2016 Category: Consumer Health News Tags: Stroke Source Type: news

Early aspirin benefits after minor stroke ‘underestimated’
A meta-analysis of individual patient data has thrown light on the benefits of aspirin for secondary prevention in patients with ischaemic stroke.
Source: MedWire News - May 19, 2016 Category: Consumer Health News Tags: Stroke Source Type: news